Evidence map›Paper›PMID 34793686›Full record

ArticleExpert opinion on therapeutic targets2021

Tanya M Monaghan, Anna M Seekatz, Benjamin H Mullish, Claudia C E R Moore-Gillon, Lisa F Dawson, Ammar Ahmed, Dina Kao, Weng C Chan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert opinion on therapeutic targets, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Development of a high-throughput screening platform forAntimicrobial agents and chemotherapy · 2026
    Article
  2. Review
  3. Insights into the Evolving Epidemiology ofAntibiotics (Basel, Switzerland) · 2023
    Review
  4. Article
  5. The Urgent Threat ofBiomedicines · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Tanya M MonaghanNIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK.ORCID 0000-0001-7622-3997
Anna M SeekatzBiological Sciences, Clemson University, Clemson, SC, USA.
Benjamin H MullishDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.ORCID 0000-0001-6300-3100
Claudia C E R Moore-GillonDivision of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
Lisa F DawsonDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0003-4644-2368
Ammar AhmedNIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK.
Dina KaoDepartment of Gastroenterology, Zeidler Ledcor Centre, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-6096-0586
Weng C ChanSchool of Pharmacy, Biodiscovery Institute, University of Nottingham, University Park, Nottingham, UK.
University of Nottingham · GBImperial College Healthcare NHS Trust · GBClemson University · USLondon School of Hygiene & Tropical Medicine · GBUniversity of Alberta · CA

Funding

Critical functions of the gut microbiota that mediate recovery from recurrent Clostridium difficile infectionK01DK111794 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SEEKATZ, ANNA MARIA · 2018 to 2022
$706k
Medical Research Council MC_PC_15033Medical Research Council MR/S019103/1NIDDK NIH HHS K01 DK111794
6 · The paper itself

Abstract

introductionAREAS COVERED: We searched PubMed and Web of Science databases for articles identifying novel therapeutic targets or treatments for EXPERT OPINION: Considerable progress has been made in the development of new anti-CDI drug candidates. Nevertheless, a greater comprehension of CDI pathogenesis and host-microbe interactions is beginning to uncover potential novel therapeutic targets, which can be exploited to plug gaps in the CDI drug discovery pipeline.

Indexed as

Clostridioides difficileClostridium InfectionsClostridioidesHumansClostridioides difficile infectionnew drug targetssmall inhibitorstherapeuticstoxinsvirulence factors

Identifiers

PMID34793686
PMCPMC12107399
OpenAlexW3212864445

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.